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To understand why cross-species infection of prion disease often 
results in inefficient transmission and 
reduced protein conversion, most research 
has focused on defining the effect of varia-
tions in PrP primary structures, including 
sequence compatibility of substrate and 
seed. By contrast, little research has been 
aimed at investigating structural differ-
ences between different variants of PrPC 
and secondary structural requirements 
for efficient conversion. This is despite 
a clear role for molecular chaperones in 
formation of prions in non-mammalian 
systems, indicating the importance of 
secondary/tertiary structure during the 
conversion process. Recent data from our 
laboratory on the cellular location of dis-
ease-specific prion cofactors supports the 
critical role of specific secondary struc-
tural motifs and the stability of these 
motifs in determining the efficiency of 
disease-specific prion protein conversion. 
In this paper we summarize our recent 
results and build on the hypothesis pre-
viously suggested by Wuthrich and col-
leagues, that stability of certain regions 
of the prion protein is crucial for protein 
conversion to abnormal isoforms in vivo. 
It is suggested that one role for molecular 
cofactors in the conversion process is to 
stabilize PrPC structure in a form that is 
amenable for conversion to PrPSc.
Introduction
Prion diseases in mammals, or transmissi-
ble spongiform encephalopathies (TSEs), 
exist as a family of different strains 
that appear to be encoded by distinct 
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conformations1 of the disease-associated 
form of the prion protein, PrPSc. How a 
single, rather small protein can fold into 
multiple discrete structures that are all 
capable of causing disease remains puz-
zling. It has been hypothesized that strain-
specific cofactors exist that are capable of 
catalyzing the formation of PrPSc-like 
conformations2-4 from the native isoform, 
PrPC. Indirect evidence for the existence of 
cofactors comes from the repeated failure 
to refold purified recombinant PrP 
(recPrP) into a structure that recapitulates 
the infectivity levels associated with PrPSc 
or replicates all characteristics of a natural 
TSE disease.5-8 However, the Supattapone 
laboratory has recently published studies 
demonstrating that purified PrPC can be 
refolded, in the presence of lipid, nucleic 
acid and a seed of PrPSc, into forms that 
are fully infectious.9-11 Earlier this year, 
these studies culminated when Wang 
et al.12 published results that appear to 
show the generation of prion infectivity 
from recombinant PrP and purified com-
ponents in the absence of PrPSc. Many 
of these recent studies use the protein 
misfolding cyclic amplification (PMCA) 
technology13 to induce misfolding. This 
technique incorporates sequential sonica-
tion steps, presumably to break up aggre-
gates and propagate greater quantities 
of smaller seeds.14 However, there are a 
range of problems associated with the use 
of sonication to aid protein misfolding; 
sonication is clearly non-physiological 
and the energy imparted may overcome 
the absence of as yet undiscovered cofac-
tors. The lack of quantitative data from 
PMCA applications does not allow certain 
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of fractions 1, 2 and 10, as monitored by 
thioflavin T (ThT) fluorescence, together 
with a bar chart of lag times of all fibrilliza-
tion reactions. These data essentially rep-
licate our previous findings using murine 
recombinant PrP; low density fractions 
that enhance cell-free conversion (fractions 
2–5) also inhibit fibrillization, in this case 
across an ovine-murine species barrier, fur-
ther demonstrating the lack of specificity 
of the cofactors present in the subcellular 
fractions.
If the cofactors present in our low 
density subcellular fractions act non-spe-
cifically, both in terms of TSE strain and 
species, to enhance disease-specific prion 
protein misfolding and inhibit in vitro 
fibrillization, then what is the mecha-
nism of action? Furthermore, how are 
species barriers mediated and what limits 
the ability of different scrapie strains to 
infect particular cells and/or individuals? 
Traditional dogma suggests that compat-
ibility between exogenous PrPSc and host 
PrPC is an important factor in mediat-
ing species barriers24 but is not sufficient 
to explain all aspects of TSE infections. 
Equally, cell-specific strain tropism is 
believed to result from restricted expression 
of cellular cofactors,1 but our data argues 
against this. Differential clearance of PrPSc 
from TSE-infected cells may also play a 
key role in suppressing certain infections, 
be that different TSE strains or infections 
passed from other species. Certainly, our 
data, albeit using in vitro systems, sug-
gest that cell-derived, low density cofac-
tors may help replicate all forms of TSE 
disease and that some mechanisms lim-
iting infection may operate on a cellular 
rather than molecular level.
Suggestions of how our cell-derived 
cofactor preparations may function can 
be derived by considering details of the 
two different conversion systems used. 
The CFCA uses physiological salts supple-
mented with detergent and a seed of PrPSc 
to convert recombinant PrP. Basic research 
into the mechanism of this assay suggests 
that the correct fold of the substrate is 
essential,25 although sub-denaturing con-
centrations of guandinium hydrochloride 
can also enhance the assay efficiency, pre-
sumably by “loosening” the structure of 
PrPSc. Conversely, the fibrillization experi-
ment, as pioneered by Baskakov et al.23 
resulted in degradation of the recombi-
nant PrP substrate, which demonstrates 
the presence of proteases in those prepara-
tions. Crucially, however, we found some 
subcellular fractions that double the effi-
ciency of conversion of recombinant PrP 
compared to control reactions. Subcellular 
fractions were prepared by ultracentrifu-
gation through a gradient of OptiPrep and 
fractions enhancing PrP conversion were 
from the top of the gradient, representing 
low density species. We showed that these 
low density fractions were composed of 
proteins from both the cell membrane and 
the cytoplasm and enhancement of PrP 
conversion proceeded in a dose-dependent 
manner. Thus, the moieties in these frac-
tions enhance cell-free conversion and are 
putative prion misfolding cofactors.
In order to test specificity of these 
results, we used a conversion system seeded 
with PrPSc derived from mice infected with 
ME7 scrapie and demonstrated enhanced 
conversion in the presence of low density 
fractions from both ME7-susceptible LD9 
cells and ME7 non-susceptible SMB cells.22 
This result was surprising since SMB cells 
are not susceptible to stable infection with 
ME7 scrapie (Ruth Hennion, personal com-
munication), a phenomenon that has been 
suggested to result from the lack of strain-
specific cofactors.1 A similar result was 
achieved using low density fractions from 
LD9 cells and a conversion assay system 
seeded with PrPSc from the 79A strain of 
scrapie, a strain that has not been shown 
to infect LD9 cells.3 Thus, we concluded 
that the effects of the subcellular fractions 
on conversion were at least partly non-
specific. In order to investigate the mecha-
nism of conversion enhancement, we also 
tested the effect of these subcellular frac-
tions on an alternative misfolding pathway 
of PrP: denaturant- and shaking-induced 
fibrillization.23 Surprisingly, the same 
low density, subcellular fractions that 
enhanced disease-specific misfolding in the 
CFCA inhibited fibrillization of recombi-
nant murine PrP. In more recent work, we 
have also tested the species specificity of 
subcellular fractions by fibrillizing ovine 
recombinant PrP in the presence of the 
fractions (derived from the murine LD9 
cell line). The results are summarized in 
Figure 1, which shows fibrillization curves 
of ovine recombinant PrP in the presence 
mechanistic aspects of protein misfolding 
to be investigated and sonication has also 
been shown to generate amyloid-like fibrils 
from proteins not known to fibrillize in 
vivo.15,16 Even in the absence of known 
prion cofactors or understanding of the 
role of sonication in prion amplification, it 
is critically important to investigate prion 
misfolding mechanisms under physiologi-
cal conditions.
We have traditionally used a modified 
version17 of the cell-free conversion assay 
(CFCA), a technique pioneered during the 
1990s by the group of Byron Caughey.18 
This assay is a physiological prion conver-
sion system that mimics many aspects of 
TSE disease, including species barriers and 
the effect of polymorphisms. Conversion of 
recombinant PrP in the assay is also inhib-
ited by known anti-prion drugs.19 By use 
of the CFCA, we have recently published 
two studies20,21 that appear unrelated, but 
which taken together suggest that partially 
stabilizing the structure of PrPC in a form 
that is amenable for conversion to PrPSc is 
a potential role for prion cofactors. Our 
data agree with and extend previous obser-
vations on the balance between different 
misfolding pathways of PrP and the role of 
key areas of secondary structure of PrPC in 
directing conversion.
Specific Fractions  
of Scrapie-Susceptible Cells  
Enhance Disease-Specific PrP 
Misfolding but Inhibit  
Generic Misfolding
In work published in the Journal of 
Biological Chemistry,20 we described 
experiments by which we investi-
gated the location of prion conver-
sion cofactors through fractionation of 
scrapie-susceptible cells and use of the 
subcellular fractions to supplement our 
cell-free conversion assay. The CFCA 
involves the incubation of recPrP with a 
seed of PrPSc enriched from mouse brains 
and, after proteinase K (PK) digestion, we 
can measure the amount of recPrP that has 
converted to a protease-resistant isoform, 
following which the percent efficiency of 
conversion can be assessed.17 We found 
several subcellular fractions that had little 
or no effect on conversion efficiency when 
added to the assay while other fractions 
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been shown to have profound effects on 
the susceptibility of sheep to both natural 
and experimental scrapie.28 One such 
polymorphism, discovered recently by col-
leagues at The Roslin Institute, involves 
the amino acid substitution Pro-Leu at 
codon 168 (P168L) and the mutation con-
fers dramatically increased resistance of 
sheep to experimental BSE infection.29 We 
previously showed that recombinant ovine 
PrP carrying the P168L substitution was 
resistant to conversion in vitro and, fur-
thermore, that murine PrP carrying the 
equivalent substitution (P164L) was also 
resistant to conversion.30 To investigate 
the mechanism of this polymorphism-
mediated resistance to conversion (and 
disease) we expressed a range of murine 
proteins carrying different substitutions at 
codon 164 (164P, 164L, 164Q, 164E and 
164S) and studied the thermal stability of 
the proteins and their ability to convert to 
a protease-resistant isoform in the CFCA. 
We found a correlation between stability 
implications for therapeutics that seek to 
stabilize the structure of PrPC; they may 
inadvertently stabilize PrPC in a struc-
ture more amenable for disease-specific 
conversion.
An Ovine-Specific Mutation  
Reduces Stability  
of Murine Recombinant PrP  
but Also Reduces Efficiency  
of Conversion
We have also recently published work in 
Biochemistry21 that indirectly supports the 
hypothesis that a well-folded and stable 
structure for PrPC is critically important 
for efficient conversion to PrPSc. This paper 
describes experiments in which we inves-
tigated the effect of a specific polymor-
phism in ovine PrP and the data obtained 
may point, more generally, to principles 
underlying PrP structure and conversion. 
The ovine prnp gene is highly polymor-
phic and a number of polymorphisms have 
proceeds under more denaturing condi-
tions and the results of various experiments 
suggest that at least partial unfolding of 
the recPrP to a prefibrillar intermedi-
ate is an important step in this assay.26,27 
For example, Figure 2 shows the effect 
of reduced guanidine concentrations on 
fibrillization of murine PrP; as the con-
centration of guanidine is reduced from 
2 to 0.24 M the lag time to fibrillization 
increases dramatically in both unseeded 
assays and those seeded with preformed 
fibrils. Thus, it is clear that partially dena-
turing the structure of recombinant PrP 
favors formation of non-disease-specific 
isoforms, while maintaining and possibly 
stabilizing the structure of recombinant 
PrP aids formation of disease-specific 
structures. A basic schematic depicting 
this balance is shown in Figure 3. Solution 
conditions or molecular cofactors could, 
therefore, tip the balance of the “folded ↔ 
partially folded” equilibrium in one direc-
tion or the other. If true, this finding has 
Figure 1. Fibrilization of ovine PrP, monitored by thioflavin T fluorescence, in the presence of subcellular fractions of murine LD9 cells. (A) Fraction 1  
(B) Fraction 2 (C) Fraction 10 (D) Bar chart showing lag times to fibrilization of ovine PrP in the presence of all 22 fractions produced by fitting sigmoidal 
curves to raw ThT fluorescence data. Reactions supplemented with fractions 2–5 did not fibrilize completely in the time frame of the assay (24 h) 
hence sigmoidal cures could not accurately be fitted to allow lag times to be calculated. The same fractions (2–5) were previously shown to enhance 
conversion of PrP to a protease-resistant isoform in the cell-free conversion assay. The +ve control relates to fibrilization reactions to which no 
subcellular fractions were added.
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converts efficiently in the CFCA and is 
thermally more stable. Oligomerization 
of recombinant PrP was carried out under 
partly denaturing conditions at acidic 
pH,31 thus our data is consistent with an 
increased tendency of unstable proteins 
reduced stability promotes non-disease- 
specific misfolding, we further found that 
in vitro oligomerization of the 164L vari-
ant, which converts inefficiently in the 
CFCA and is thermally less stable, was 
more rapid than the 164P variant, which 
and extent of conversion, such that the two 
most thermally stable proteins (164P and 
164S) were converted the most efficiently, 
while the other three variants had reduced 
stability and were converted less efficiently. 
Consistent with our hypothesis that 
Figure 3. Schematic of a proposed, simplified pathway of PrP folding. Partial denaturation to an intermediate conformation promotes generic 
misfolding to oligomers and fibrils. Disease-specific misfolding proceeds from a more fully folded form, possibly by route of a different, PrPSc-induced, 
partially folded intermediate. General conditions that promote unfolding will lead more rapidly to generic misfolded isoforms, while those that 
promote stability and a more structured PrPC molecule will favor disease-specific misfolding.
Figure 2. The effect of guanidinium hydrochloride concentration on fibrillization of murine PrP. Guanidine in the final reaction was titrated and 
lag times to fibrillization of either unseeded (white bars) or seeded (filled bars) reactions were calculated by fitting sigmoidal curves to raw ThT 
fluorescence data. For unseeded reactions at low guanidine concentrations the protein did not fibrillize to completion in the timeframe of the assay 
(24 h) hence lag times could not be calculated.
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different levels of stability around the 
β2-α2 loop region, possibly through dis-
ruption of the native salt bridges45 in PrPC, 
and that no other protein was involved. 
The recent finding that the effects of chi-
meric murine/human prion proteins are 
replicable in purified systems in vitro adds 
weight to this argument.46 Thus, several 
lines of evidence support the hypothesis 
that stability in PrPC and, in particular the 
β2-α2 loop region, is a critical determi-
nant for disease-specific prion misfolding.
While there exists significant evidence 
supporting the importance of stability, 
there are also elements of TSE science 
that argue against prion protein stability 
as a general factor in determining dis-
ease susceptibility. Firstly, many disease-
associated mutations in the human prion 
gene appear to reduce protein stability, 
apparently in direct disagreement with 
our hypothesis. However, the diseases that 
result from prion mutations do so without 
apparent exogenous infection and mani-
fest only late in life, suggesting that the 
proteins involved may have compromised 
conversion efficiency once the misfolding 
cascade has started. Other disease-causing 
mutations have little effect on stability or 
are slightly stabilizing and despite much 
research (reviewed in ref. 47) mechanistic 
aspects of these mutations remain to be 
established. Secondly, the recently identi-
fied atypical scrapie has a pattern of sus-
ceptibility that is essentially the reverse 
of that known for classical scrapie, such 
that sheep expressing proteins that are less 
stable are more susceptible to disease.48 
While atypical scrapie has been shown 
to be transmissible,49 the small number 
of cases encountered and late age of onset 
is more suggestive of a sporadic disease 
and in such cases a less stable protein 
may be critical to initiate the infection. 
The structure of the PrPSc deposited dur-
ing pathogenesis of atypical scrapie also 
appears different to that formed during 
classical scrapie, as evidenced by the 
presence of a low molecular weight iso-
form after proteinase K digestion.50 This 
is somewhat more reminiscent of the 
PK-resistant cores of certain forms of 
sporadic CJD and fibrils of recombinant 
PrP.51 As more research in this area is pub-
lished it may become evident that protein 
stability is important only for certain TSE 
mobile and Gossert et al. argued that a 
“rigid loop” may correlate with prion dis-
ease susceptibility. Support for this comes 
from the finding that bank vole PrP also 
contains a rigid β2-α2 loop37—bank voles 
are highly susceptible to many strains of 
TSE disease38 and the reasons for this 
have been tracked to specific amino acid 
residues in the loop region of bank vole 
PrP that affect protein misfolding both 
in vitro39 and in vivo.40 As previously dis-
cussed, the β2-α2 loop contains the poly-
morphic ovine residues 168 and 171, key 
determinants of the susceptibility of sheep 
to prion disease and mediators of protein 
stability.
If a rigid β2-α2 loop is responsible for 
increased susceptibility of cervids to TSE 
disease then engineering such a loop in the 
prion protein of an alternate species should 
render that species more susceptible than 
wildtype counterparts. Sigurdson et al. 
created transgenic mice expressing PrP 
in which two endogenous murine amino 
acids of the loop region had been replaced 
by cervid counterparts41 at codons 169 
and 173. These mice, therefore, expressed 
“rigid loop” PrP and the mice acquired a 
spontaneous neurodegenerative disease 
that was transmissible. The mice are also 
differentially susceptible to prion diseases 
from a variety of species and susceptibility 
was shown to be determined by compat-
ibility between the amino acid at codon 
169 in inoculum (PrPSc) and host (PrPC) 
prion proteins.42 At a protein level, we 
have recently confirmed that the doubly-
mutated murine protein (S169N, N173T) 
is thermally more stable than wildtype 
mouse PrP and fibrillizes less readily 
(Agarwal et al. in preparation) consistent 
with out proposed misfolding pathway in 
Figure 3. It is also notable that this is the 
region of the protein that was suggested to 
bind to the putative cofactor protein X.43 
The involvement of a proteinaceous cofac-
tor was invoked to explain the differential 
susceptibility of transgenic mice expressing 
various mouse/human chimeric PrP mol-
ecules. However, a similar experiment 
involving mouse/cattle chimeric protein44 
failed to replicate the previous results, 
casting the involvement of protein X into 
doubt. While it remains to be tested, it 
appears plausible that the different pro-
tein variants involved in the studies have 
to adopt intermediates on the pathway 
to generically misfolded isoforms. These 
observations agree with the basic sche-
matic depicted in Figure 3.
Other than codon 164 amino acid 
changes, the destabilizing effects of other 
amino acid substitutions on PrP structure 
have been published, most notably ovine-
specific polymorphisms.32-34 These studies 
indicate that the substitution Gln-Arg at 
codon 171, which is close to residue 168 
and is associated with extreme resistance of 
sheep to classical scrapie, produces a pro-
tein with reduced stability. This effect has 
been used to posit the hypothesis that such 
proteins misfold generically in vivo more 
readily and hence are cleared more rapidly 
leading to reduced protein half-life and 
reduced potential substrate for conversion. 
It is not facile to generate directly com-
parable data when measuring differences 
in protein turnover rates as a function of 
amino acid changes and this hypothesis 
remains controversial. However, our data 
would suggest that increased turnover of 
“resistant” proteins need not be the only 
mechanism by which disease resistance 
is modulated. Instead, we note that less 
stable protein variants convert less readily 
in the CFCA, a system in which increased 
protein turnover cannot be invoked as an 
argument.30 This leads to the conclusion 
that a stable and well-folded substrate is 
a prerequisite for efficient conversion, a 
conclusion that correlates directly with 
our proposed mechanism for the enhance-
ment of conversion by our low density 
subcellular fractions.
Further evidence of the role of stability 
in this region of PrP comes from studies of 
the molecular differences between cervid 
and murine PrP. Cervids appear exception-
ally susceptible to chronic wasting disease 
(CWD) and it has always been puzzling 
why the disease has spread so readily in elk 
and deer in the US. Part of this appears to 
involve the ready secretion of CWD infec-
tivity from deer,35 but following determi-
nation of the NMR structure of elk prion 
protein by the group of Wuthrich, another 
possible reason for the apparent suscep-
tibility of deer became apparent.36 The 
deer prion protein contains a well defined 
loop region connecting the second β-sheet 
to the second α-helix. In most other spe-
cies studied, this loop is at least partially 
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detected after proteasome inhibition52 and 
these are most likely aberrantly folded PrP 
isoforms, formed in the ER/golgi body 
during normal post-translational folding 
and targeted for proteasomal degradation. 
Either cellular site, therefore, represents a 
plausible location for a prion conversion 
cofactor, with recent data from the Soto 
laboratory suggesting that prion cofactors 
may reside predominately on the plasma 
membrane.4
If prion cofactors are either cytoplas-
mic or located on or around the plasma 
membrane, then do any known bind-
ing partners fit this expression profile? 
Alternatively, can molecules used in other 
misfolding studies be identified that 
may represent our conversion-enhancing 
cofactors? Putative prion protein interac-
tion partners have been identified in an 
increasing number of studies and include, 
amongst others, N-CAM,53 37–67 kDa 
laminin receptor precursor,54 LRP-1,55 
glypican-1,56 glycosaminoglycans and pro-
teoglycans57 (including heparin and chon-
droitin sulphates), nucleic acids,58 anionic 
lipids59 and copper ions.60 In short, almost 
all subsets of biomolecules are repre-
sented, many of which can be found in the 
literature we can speculate on the pres-
ence of particular molecules or molecular 
subsets that may increase PrPC stability. In 
our previous work we probed subcellular 
fractions for markers of specific organelles 
by western blotting and found that active 
fractions contained the plasma membrane 
marker annexin II. By use of proteomic 
methods, we also found a large number of 
cytoplasmic proteins in low density sub-
cellular fractions20 and certain aspects of 
PrP cell biology could allow interactions 
with molecules in either location. After 
expression in the ER, PrPC is secreted 
and is anchored on the cell membrane 
by means of its glycosylphosphatidyl ino-
sitol membrane anchor. Here PrPC has 
been shown to be localized to detergent-
resistant membranes (lipid rafts), but then 
leaves these to be endocytosed and recy-
cled. Thus, interaction with other mole-
cules on the plasma membrane is not only 
likely to allow PrPC to carry out its normal 
function, but interaction with a receptor 
is an obligatory step in endocytosis of a 
molecule without cytoplasmic domains. 
Likewise, although PrPC is probably not 
localized to the cytoplasm during its nor-
mal cell biology, cytoplasmic PrP has been 
strains. It is also possible that, while stabil-
ity in the loop region is important for effi-
cient conversion, reduced stability in other 
regions may also play a role in mediating 
conversion. Due to loss of key hydrogen 
bonds or salt bridges, it is possible that 
single amino acid substitutions can have 
stabilizing effects in some parts of the mol-
ecules but destabilizing effects in others. 
Hence, the importance of secondary struc-
tural stability in protein conversion may 
be dependent on the particular amino 
acid substitution, prion protein structural 
motif or TSE strain in question.
What are the In Vivo Cofactors 
that Enhance Prion Conversion  
in Our Low Density  
Subcellular Fractions?
Although our combined data are consis-
tent with alterations in conversion effi-
ciency resulting from the ability of low 
density subcellular fractions to modulate 
protein folding and stability, we do not 
yet know the identities of the conver-
sion enhancing cofactors. By use of what 
knowledge we have about our low den-
sity fractions and comparisons to recent 
Figure 4. Western blot of the cell-free conversion assay of 3F4 antibody-tagged murine recombinant PrP in the presence of glycogen. Assays were 
seeded with PrPSc purified from ME7-infected mice and, in each case, 9/10th of the reaction was treated with PK while the remaining 1/10th was not. In 
the absence of PrPSc, recombinant PrP is digested away by PK (lanes 1 and 2) while in the presence of PrPSc a protease-resistant isoform is produced 
(lanes 3 and 4). In the presence of low concentrations of glycogen, cell-free conversion is inhibited (lanes 5–7) while at higher concentrations of 
glycogen conversion is similar to control levels (lanes 9 and 10). Lanes 11–14 contain the non-PK treated samples in the presence of glycogen to 
demonstrate that similar levels of recPrP substrate were present in each assay.
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structural stability of the protein is not 
known and the mechanism by which both 
CFCA and PMCA assays are enhanced 
by polyanionic substances is not clear. 
Likewise, although the interaction of PrP 
with lipids has been studied extensively,70 
the mechanism of its apparent role as a 
cofactor in PrP amplification studies is 
not known and may simply bring together 
PrPC and PrPSc in vesicles to facilitate con-
version. It remains possible that our low 
density fractions that enhance cell-free 
conversion contain both lipids and poly-
anionic species and the mechanism of 
conversion enhancement is similar to that 
described in PMCA studies.
An interesting variation to the con-
stituents used for PMCA studies has been 
reported by Murayama et al.71 In their 
studies they found that the spontaneous 
formation of non-disease-specific protease- 
resistant PrP could be inhibited by the 
addition of digitonin, a glycoside that aids 
solubilization of lipids and membrane pro-
teins. Digitonin consists of a steroid cova-
lently linked to a small sugar moiety and 
the stabilizing effect of small saccharides, 
such as trehalose,72 on protein structure is 
well known. It is likely that digitonin helps 
to maintain the structural stability of the 
PrP substrate during PMCA applications, 
thereby inhibiting non-specific fibril-
lization and promoting disease-specific 
misfolding.
Heat shock proteins as potential cofac-
tors in mammalian systems. In yeast, a 
system that is genetically tractable, the 
importance of heat shock proteins (HSPs) 
in propagation of the prion states is well 
established,73 although the exact role 
of each HSP is still the subject of much 
research. HSPs can function by ensur-
ing that individual proteins are correctly 
folded but also appear to help in disaggre-
gating misfolded protein aggregates. It has 
been suggested continually that HSPs are 
important in mammalian prion diseases 
and various members of the HSP family 
have been found to bind PrPC,74 copurify 
with PrPSc fibrils65 or aid the conversion 
process in vitro.75 We know that cytoplas-
mic HSPs are present in our low density 
subcellular fractions since Hsp90 isoforms 
were detected by proteomic methods. 
They may represent the cofactors that 
enhance cell-free conversion by ensuring 
SAF preparations.65-67 Co-purifying pro-
teins include ferritin, CaMKII and vari-
ous cytoskeletal and structural proteins 
including actin and tubulin isoforms. 
However, some previous studies omitted 
control preparations from either unin-
fected or PrP-null mice in proteomic iden-
tifications; we have found that some of the 
proteins previously suggested to be spe-
cific to SAF preparations are also purified 
after performing mock SAF preparations 
on control brains, a finding confirmed 
by Moore et al.67 This presumably results 
from the large size and general insolubil-
ity of these proteins. Ferritin, for example, 
exists as a multimer of molecular weight 
~0.5 MDa but can form higher molecu-
lar weight oligomers. We have compiled 
lists of proteins that are present specifi-
cally in SAF preparations after subtrac-
tion of those proteins co-purifying simply 
because of their biophysical properties 
(Graham et al. in preparation). Within 
the refined list are several proteins that are 
usually resident on the plasma membrane, 
cytoskeletal proteins and some cytoplas-
mic proteins. We are currently trialing 
these proteins for their ability to enhance 
prion protein misfolding in the cell-free 
conversion assay and their effects on sta-
bility of the structure of recombinant PrP.
Molecules used in misfolding studies 
to generate de novo infectivity. Initial 
studies reporting the generation of prion 
infectivity de novo from purified com-
ponents revealed the role for both lipids 
and specific nucleic acids (poly(A)RNA) 
in enhancing conversion of PrP. However, 
recent data from use of PMCA suggest 
that the requirement for nucleic acid 
for efficient prion amplification may be 
species-dependent; cofactors for propaga-
tion of murine and bank vole PrPSc were 
degraded by proteases indicating that 
they are at least partially proteinaceous 
in nature.68 It is also worth noting that 
nucleic acid can be replaced by similarly 
charged glycosaminoglycans in hamster 
PMCA systems9 indicating that the mode 
of action for such cofactors may be related 
to charge and, on this basis, they may be 
playing a biophysical structural role as 
opposed to a biological functional role. 
Glycosaminoglycans have been shown to 
stimulate cell-free conversion of recom-
binant PrP69 although their effect on the 
extracellular milieu, on the plasma mem-
brane or in the cytoplasm, and the result 
is a minefield of information, with many 
molecules representing possible cofac-
tors but few with functional data in this 
regard. The interactome of PrPC is there-
fore not particularly useful for identifying 
putative cofactors,61,62 but a range of other 
published studies provide more specific 
cofactors that may be involved in altering 
PrPC stability.
Identification of molecules co-puri-
fying with PrPSc in scrapie-associated 
fibrils. One of the more obvious places 
to look for prion cofactors is in the PrPSc-
containing plaques and fibrils that are 
deposited during TSE disease. If cofactors 
are involved in the PrPC-PrPSc misfolding 
process then it seems reasonable that 
they should become integrated into the 
growing fibril. Various molecules have 
been suggested to co-purify with PrPSc in 
scrapie-associated fibrils (SAF) including 
polysaccharide (which may act as a scaf-
fold), small nucleic acids (see below) and 
other proteins. The polysaccharide has 
been suggested to consist of α-linked poly-
glucose, similar to glycogen,63 and purified 
glycogen was shown to promote fibrilliza-
tion of PrP in vitro.64 We have also tested 
glycogen in the cell-free conversion assay 
for its ability to enhance PrPSc catalyzed 
misfolding. Typical results are shown in 
Figure 4 and show clearly that, at low 
concentrations, glycogen inhibits disease-
specific misfolding of PrP, although this 
effect is diminished at higher concentra-
tions. This is a curious result and suggests 
that the effect of glycogen is related to its 
concentration, perhaps through formation 
of glycogen multimers at higher concen-
tration that lose inhibitory activity. In any 
case, based on the previous fibrillization 
data, inhibition of cell-free conversion at 
low glycogen concentration is surprising, 
but suggests that glycogen may not act as 
a prion conversion cofactor. The opposite 
effects of glycogen on in vitro fibrilliza-
tion and cell-free conversion, however, 
agree with our model of PrP misfolded 
presented in Figure 3 and suggest that 
glycogen may act, at low concentrations, 
to destabilize recombinant PrP structure.
By use of proteomic techniques, 
several groups have identified differ-
ent proteins co-purifying with PrPSc in 
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a correctly folded substrate and may act 
similarly to inhibit in vitro fibrillization 
of recombinant PrP. Whether cytoplas-
mic HSPs interact with PrPC in vivo is 
not clear, although retrograde transport 
of PrPC from the endoplasmic reticulum 
to the cytoplasm provides a mechanism by 
which this interaction may occur.52
Experimental Procedures
All experimental procedures used to gen-
erate data shown in this paper have been 
previously published.20,21
Conclusion
Contrary to expectations, resistance-
associated PrPC proteins appear less stable 
than proteins associated with disease sus-
ceptibility, highlighting the possibility 
that a stable PrP molecule, in particular 
the β2-α2 loop, may be a prerequisite for 
efficient PrP conversion in acquired prion 
diseases. Our recent data supports this 
hypothesis through the identification of 
PrP loop mutants that correlates stability 
with in vitro conversion and through the 
identification of low density subcellular 
fractions that enhance cell-free conversion 
but inhibit fibrillization. To fully under-
stand implications of both findings for 
TSE disease it will be important to define 
completely the role of PrP structure in the 
conversion process.
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